The 18 most recent market catalysts affecting $NEO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains NeoGenomics at Buy, Raises Price Target to $23
TD Cowen, a prominent investment bank, has maintained its 'Buy' rating on NeoGenomics and significantly raised its price target from $19 to $23. This action indicates a strengthene…
Oct 28, 2026
Corporate Catalyst
Neutral
Impact 92
NeoGenomics Reports Third Quarter 2026 Results
NeoGenomics, Inc. announced its third-quarter 2026 financial results, reporting revenue of $209.3 million and adjusted EPS of $0.07. Both figures surpassed FactSet consensus estima…
Oct 6, 2026
Corporate Catalyst
Bearish
Impact 75
What's Going On With NeoGenomics Stock Tuesday?
NeoGenomics announced a significant leadership transition, with current President and COO Warren Stone taking over as CEO from Tony Zook, who will become executive chair. This type…
Oct 6, 2026
Corporate Catalyst
Bullish
Impact 55
StoneX Maintains Buy on NeoGenomics, Raises Price Target to $20
StoneX analyst Bruce D. Jackson maintained a 'Buy' rating on NeoGenomics (NEO) and raised the price target from $16 to $20. This action signals increased confidence from a prominen…
Oct 6, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on NeoGenomics, Raises Price Target to $22
Needham analyst Mike Matson has maintained a 'Buy' rating on NeoGenomics (NEO) and raised the price target from $19 to $22. This action signals a continued positive outlook from a …
Oct 6, 2026
Corporate Catalyst
Bullish
Impact 65
BTIG Upgrades NeoGenomics to Buy, Announces $28 Price Target
BTIG analyst Mark Massaro upgraded NeoGenomics (NEO) from Neutral to Buy and announced a $28 price target. This analyst upgrade signals increased confidence in NeoGenomics' prospec…
Oct 5, 2026
Corporate Catalyst
Bearish
Impact 75
Neostellar Capital Estimates Q3 NAV Of $12.25-$12.75/Share, Down From $13.44/Share At June 30
This headline indicates a significant decline in Neostellar Capital's Net Asset Value (NAV) for Q3, which is a direct measure of the fund's performance. A falling NAV can erode inv…
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 75
NeoGenomics Sees Q3 Revenue Of About $209M; Reiterates FY2026 Revenue, Adjusted EBITDA Guidance, Expects To Raise Revenue Guidance Midpoint On Q3 Call
NeoGenomics announced preliminary Q3 2023 revenue of approximately $209 million, exceeding the previously guided range of $200 million to $205 million. This strong performance sugg…
Oct 5, 2026
Corporate Catalyst
Neutral
Impact 65
NeoGenomics Appoints President, COO Warren Stone As CEO, Effective Jan, 4 Next Year, Succeeding Tony Zook; Zook Appointed Executive Chair, Succeeding Lynn Tetrault
NeoGenomics is implementing a planned leadership succession, with Warren Stone taking over as CEO in January 2027 and current CEO Tony Zook transitioning to Executive Chair. This l…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 85
NeoGenomics shares are trading higher after the company announced that its RaDaR ST molecular residual disease assay has received expanded coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program.
The expanded Medicare coverage for NeoGenomics' RaDaR ST assay is a major positive development, directly increasing the potential revenue stream for this specific product. This typ…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 65
NeoGenomics’ RaDaR ST Molecular Residual Disease Assay Receives Expanded Coverage From CMS’ MolDX To Include Immunotherapy Monitoring For Patients With Late-Stage Solid Tumors
NeoGenomics' RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from CMS' MolDX program. This new coverage allows for the use of RaDaR ST in monitoring …
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 95
Neo Performance Materials Q2 Adj. EPS $0.51 Beats $0.40 Estimate, Sales $205.748M Beat $169.140M Estimate
Neo Performance Materials reported Q2 adjusted EPS of $0.51, significantly beating the $0.40 estimate by 27.5%, and sales of $205.748 million, surpassing the $169.140 million estim…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
NeoGenomics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline is a significant corporate catalyst for NeoGenomics (NEO). Beating Q2 expectations and, more importantly, raising long-term guidance (FY26 sales) indicates strong und…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
This filing highlights significant pre-market price movements across a dozen healthcare stocks, with several experiencing double-digit percentage changes. The primary catalyst for …
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on NeoGenomics, Raises Price Target to $19
This 8-K filing discloses that Needham analyst Mike Matson has maintained a 'Buy' rating on NeoGenomics (NEO) and raised its price target from $15 to $19. This analyst action is a …
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 75
NeoGenomics Raises FY2026 Sales Guidance from $797.000M-$803.000M to $802.000M-$806.000M vs $800.433M Est
NeoGenomics (NEO) has filed an 8-K to announce an upward revision to its fiscal year 2026 sales guidance. The company increased its outlook from $797 million-$803 million to $802 m…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 75
NeoGenomics Q2 Adj. EPS $0.05 Beats $0.03 Estimate, Sales $202.000M Beat $196.997M Estimate
NeoGenomics announced its Q2 earnings, reporting an adjusted EPS of $0.05, significantly beating the analyst estimate of $0.03, and sales of $202 million, also surpassing the $196.…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $16
Benchmark analyst Bruce D. Jackson maintained a 'Buy' rating on NeoGenomics and raised the price target from $11 to $16. This action signals increased confidence from the analyst i…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.